Celltrion boasts worldwide tech lead in biosimilars

South Korea has more biosimilar firepower than just consumer electronics convert Samsung. Celltrion, under the leadership of Seo Jung-jin, is a biosimilars "front-runner," says the CEO. Celltrion has "about four to five years" of a technology lead over rivals, he says. "There will be no serious competitor by 2015, in which period the industry's capacity will be short of demand," Seo says. Story

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.